An alternative mechanism explaining BRAFi treatment-induced tolerance, in melanoma, is represented by a cytokine-signaling network involving TAM-derived IL-1β and CAFs-derived CXCR2 ligands [15]. The gene discussed is IL1B; the disease is melanoma.